Absci is trading 5.57% higher at $10.71 on September 30, 2026, with no clear company-specific catalyst for the intraday move identified in available coverage.
- The latest identified company update was September 24’s planned Phase 2 STORYLINE trial details for ABS-201; trial initiation is anticipated in mid-2027.
- Reuters reported U.S. futures rose after cooler-than-expected inflation data lifted rate-cut hopes. The supplied market context shows the Nasdaq up 1.03%; this may have provided support but does not establish the direct cause of Absci’s gain.